Lilly says labeling for Zyprexa and Symbyax reflects recent data

Share this article:
Eli Lilly & Co. says updated labeling for its atypical antipsychotics Zyprexa (olanzapine) and Symbyax (olanzapine and fluoxetine HCl) reflects recently completed pooled analyses of clinical trial data in adults and adolescents, information from two non-Eli Lilly studies, and discussions with the FDA.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Legal/Regulatory


Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.